Release Date:
August 12, 2022
Expiration Date:
August 12, 2023
Activity Overview
Medical Crossfire®, one of PER®’s signature educational formats, is a video-based program in which a panel of distinguished experts engage in spirted discussions and debates on a particular clinical topic. In this activity, 3 key thought leaders explore the latest data regarding current and emerging therapeutic strategies for the management of Hodgkin lymphoma (HL) and T-cell lymphoma across lines of care. This lively discussion will help place new developments into clinical context to help you optimize care for your patients with HL or T-cell lymphoma.
Target Audience
This educational program is directed toward hematologists, oncologists, pharmacists, and nurses involved in the treatment and management of HL and PTCL.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
• Assess the efficacy and safety profile for current and emerging therapies among patients with advanced HL and PTCL from landmark clinical trials as well as real-world data in the frontline setting and beyond
• Discuss current and emerging salvage and consolidation/maintenance strategies that reduce the risk of recurrence in patients with HL undergoing ASCT
• Apply evidence from landmark trials in advanced HL and PTCL to real-world case scenarios in the management of patients with these hematologic malignancies
• Plan strategies for proactively recognizing, monitoring, and managing adverse events associated with the use of novel therapies in the management of patients with HL and PTCL
Emanuele Zucca, MD
Vice Primary, Lymphoma Unit
Oncology Institute of Southern Switzerland
International Extranodal Lymphoma Study Group
Bellinzona, Switzerland
Disclosures: Grant/Research Support: Grant to Institution: AstraZeneca, BeiGene, Celgene, Incyte, Janssen, Merck, Roche; Consultant: Advisory Boards: BeiGene, Celgene, Incyte, Janssen, Merck, Roche, Celltrion Healthcare, Kyte; Other (Travel grants): AbbVie, Janssen, Roche
Massimo Federico, MD
Professor of Oncology
University of Modena and Reggio Emilia
Director of the Medical Oncology and Lymphoma Unit
Modena Cancer Center
Modena, Italy
Disclosures: Massimo Federico, MD has no relevant financial relationships with ineligible companies.
Pier Luigi Zinzani, MD, PhD
Professor, Department of Experimental, Diagnostic and Specialty Medicine
University of Bologna
Bologna, Italy
Disclosures: Consultant: Takeda, Incyte, MSD, Gilead, Roche, Kyowa Kirin, Janssen, Novartis; Speakers’ Bureau: Takeda, Incyte, MSD, Gilead, Roche, Kyowa Kirin, Janssen, Novartis
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
